NorthStar Secures Up to $185 Million Growth Financing Led by Hercules Capital to Scale Actinium-225 Production and Radiopharmaceutical Manufacturing for Next-Generation Precision Cancer Therapies
Business Wire•29/09/2026•07:00 ET
0
Whiz Insights
NorthStar Secures Up to $185 Million Growth Financing Led by Hercules Capital to Scale Actinium-225 Production and Radiopharmaceutical Manufacturing for Next-Generation Precision Cancer Therapies
* Multi-year growth-capital facility to fuel NorthStar’s commercial production scale-up of no-carrier-added Actinium-225 (n.c.a. Ac-225) to meet growing demand for next-generation targeted alpha therapies.
Get started
Create a free account to read the full story.